Conflicts of interest (COIs) are common in the practice of emergency medicine and may be present in the areas of clinical practice, relations with industry, expert witness testimony, medical education, research, and organizations. A COI occurs when there is dissonance between a primary interest and another interest. The concept of professionalism in medicine places the patient as the primary interest in any interaction with a physician. We contend that patient welfare is the ultimate interest in the entire enterprise of medicine. Recognition and management of potential, real, and perceived COIs is essential to the ethical practice of emergency medicine. This paper discusses how to recognize, address, and manage them.
C onflicts of interest (COIs) are commonly present in the practice of emergency medicine. Emergency providers practice in a variety of settings, from rural practices, to suburban settings, to large urban academic medical centers, and may be influenced by different forces. Some COIs are easy to recognize while others are more subtle and may go unnoticed. Money, fame, recognition, advancement, and the desire to "get along" are powerful influences on emergency physicians (EPs).
This article will review what constitutes a COI and the ethical challenges they present to the care of patients and to the profession. The authors will examine the areas of clinical practice (including payment models, therapeutics, and consultation), relations with industry, expert witness testimony, medical education, research, and organizations. We will give examples of clinical scenarios and offer possible solutions based on ethical reasoning and the material presented. As ethics is a branch of philosophy, the reader should recognize that there are not necessarily scientific facts to back up all of our proposed solutions. Rather, our opinions are based on balancing ethical principles and honoring our duties to the patient as our primary interest.
WHAT CONSTITUTES A CONFLICT OF INTEREST?
The National Academy of Sciences' Institute of Medicine states that, "A conflict of interest is a set of circumstances that creates a risk that professional judgment or actions regarding a primary interest will be unduly influenced by a secondary interest." 1 In most cases relevant to the practicing EP, the primary interest is the best interest of the individual patient.
The World Medical Association statement on COIs explains that a COI "is understood to exist when professional judgment concerning direct patient care might be unduly influenced by a secondary influence," 2 appearing to emphasize (emphasis added by italics) the primacy of patient care in the enterprise of medicine. The document also states that COIs exist in physician education, research, physician office practice, and selfreferrals. In the final analysis, we contend that the ultimate "instrument of measure" from a patient point of view and from an ethical point of view is what will potentially benefit the patient the most and harm them the least. Also to be considered are what is best for society and for preserving patient autonomy.
THE OVERLAPPING MULTICAUSALITY OF COIS
There are numerous types of COIs that affect the practice of emergency medicine. Much of the literature on COIs has focused on the medical profession's relationship with industry (pharma, devices, biotech, technology, etc.). Other sources of potential COI include payment incentives, professional relationships, research, academic requirements, and desire for prestige or power. Less patient-related COIs occur during medical education (whereas these don't directly affect patients they may affect the training of competent, skilled, and unbiased physicians). While many of these areas overlap, for clarity we will address them separately.
COIS IN THE PRACTICE OF EMERGENCY MEDICINE
Examples of COI in emergency medicine may include cases such as the following:
Potential COI Scenarios in the Practice of Emergency Medicine
1.
A new plastic surgeon has just come on staff at the hospital. She is very friendly and has offered to give your practice group a lecture. She leaves some business cards and popcorn for the staff and says she is happy to suture any wound. Is this ethical? Is there a COI present? 2. An article in a reputable journal suggests a rather drastic change in your approach to a clinical scenario. Are you mandated to change practice immediately? Should industry sponsorship color your opinion? 3. As a department chair, a salesperson for a new rapidonset platelet inhibitor "details, i.e., educates you with industry information" about the drug. He offers to sponsor a journal club without any mention of the drug at the event. He also offers to leave starter pack samples for patients with acute deep venous thrombosis who present after hours. Should you distribute these samples? Does it matter that samples are reserved for patients who are deemed medically indigent? 4. Your department is approached about participating in a research study by the department of neurology, a powerful department in your institution. After hours, since no research personnel will be on site, you will be asked to obtain informed consent. Does it make a difference if you will be paid for this activity or not? Does a potential conflict exist? Example of Conflict of Interest. The use of glucocorticoids in the treatment of patients with acute spinal cord injury is another area where a COI may have played a role. While efficacy is not definitively settled, the debate has been muddied by the ties of one of the original proponents to one of two manufacturers of methylprednisolone. 6 Physicians should maintain current knowledge of the medical literature. The introduction of new medications and interventions should be based on sound scientific evidence that can be replicated in various practice environments and is based on peer-reviewed literature. Because alliances with the biomedical industry may indicate a potential COI, this information should be publicly disclosed and recognized by the readers as a potential COI.
Physicians should be skeptical of claims of leaps in outcomes from medical treatments and look for the hidden hand-COIs-that may be involved. Ties to industry are often a clue.
Relations With Industry
The pharmaceutical and medical equipment industries generate the most common and relatively obvious COIs for clinicians, institutions, professional journals, and professional organizations. These COIs include research sponsorship, institutional support, overt and covert gifts, or donations that influence prescribing practices and equipment purchases. Many physicians have strongly denied that industry has had any influence on their medical practice, despite numerous studies on gifting that demonstrate that it does. 7, 8 Manufacturers have a primary duty to their shareholders to maximize profits. Since providing gifts in various forms to healthcare workers and institutions and to professional medical organizations (PMOs) has successfully advanced this goal in the past, they are inclined to continue. One commentator recently wrote, "We should not mistake business ethics for medical ethics. Both are needed but they address different domains." 9 Individual EPs often receive small, inexpensive gifts and feel indebted, which may induce them to use or advocate for specific products when they otherwise would not. Social science research suggests that even trivial gifts may produce a psychological debt. 10 This is an example of potential COI, which may be subconscious.
Patient advocacy organizations (PAOs) provide patient and caregiver-oriented education, advocacy, and support services to those patients affected by medical conditions or to their families. 11 A recent study showed that 86 of 104 PAOs reported receiving industry support. 12 Of the 104, only 27 had COI policies on their websites and 37 had industry executives on their Boards.
Historically, for the most part, the responsibility for guarding against COIs rests with the recipients of pharmaceutical and equipment industry largesse. In a move to codify requirements for transparency of physician ownership and financial interests in healthcare facilities, in 2013 the Centers for Medicare & Medicaid Services (CMS) issued so-called "Sunshine" regulations. These regulations require that in addition to ownership interests of physicians and their immediate family members in healthcare facilities, information about industry payments to physicians and hospitals for travel, research, gifts, speaking fees, and certain meals also be submitted to CMS and be made public by CMS once a year. 13, 14 Medicolegal Consultation and Testimony The adjudication of malpractice claims is an essential mechanism for the recognition of substandard care and compensation of patients who suffer as a result. 15 EPs have an important interest in maintaining practice standards and ensuring that the judgment of such standards remain within the medical community as opposed to others without medical expertise. 16 Participation as a credible and honest expert witness thus advances the interests of EPs and their patients.
Potential COIs in the areas of medicolegal consultation and testimony are both readily apparent and challenging to address. The role of the EP in serving as an expert witness is to provide professional expertise on what a typical EP should do clinically under a specified clinical circumstance-the standard of care-and sometimes to opine on causation, that is the relationship between a physician's action and the patient's adverse outcome. In the American judicial system, EPs who are engaged in medicolegal consultation are retained by one side or the other in an adversarial process. In return for providing a review of the case or further testimony by deposition or during trial, the EP receives monetary compensation. As with other forms of COI, monetary compensation naturally creates the potential for a COI. Consciously or subconsciously there may be a temptation to provide testimony in a manner such that the party who is paying the EP receives a favorable opinion. 17 As a counterbalance, attorneys recognize how payment can skew testimony and often use that compensation to impeach the testimony of physician experts, especially if it is excessive. 15, 18 To avoid COIs in medicolegal consultation and testimony, EPs should strive for objective assessment of cases grounded in the medical literature tempered with the experience of current clinical practice. It is critical to avoid the attribution of malpractice simply due to an adverse outcome and to ensure that monetary compensation to experts is equitable and market-based for the time and expertise provided. 19, 20 Medical Education Undergraduate Medical Education. Undergraduate medical education is accredited by the Liaison Committee on Medical Education. The purpose of accreditation is to ensure that graduates exhibit general professional competencies that are appropriate for entry to the next stage of their training and that serve as the foundation for lifelong learning and proficient medical care. 21 The learning environment includes both the formal curriculum, as well as the hidden curriculum, which includes institutional practices and culture.
Faculty often are active in a variety of endeavors, including clinical care, education, research, and administration. Faculty may experience a COI related to relationships with external organizations. Additionally, faculty may experience COI related to reputation or career advancement. 22 The biomedical industry may offer to provide financial support for research, education, donations for facilities or equipment, social events, gifts, or scholarships. Institutional policies that require educational or research achievements may affect faculty time allocation. The AAMC recommends that academic medical centers establish policies requiring that industry funds be given to the administration of the medical center and should have no involvement in the selection of recipients or any "quid pro quo" expectations. 23 Faculty and students may desire academic recognition, promotion, grants, or publications. Such goals may create a potential COI for the learning environment. Recognition and management of such conflicts should prevent inappropriate diversion of energy from educational endeavors or inappropriate pressures on faculty or students.
Disclosure of potential conflicts in the educational environment is essential to promote transparency and to educate students about COIs for their future careers. 24 Faculty, students, and residents should be educated on appropriate perspectives to manage potential COIs in education, research, and clinical practice. Medical education should include education regarding COI. Curricula should include disclosure of commercial interests, avoiding actual or perceived conflicts, managing interactions with drug and device companies, and mandating the exclusion of gifts. 25, 26 Over time, medical students report less exposure to drug companies and report that they feel less entitled to gifts. 27 Graduate Medical Education. The Accreditation Council on Graduate Medical Education (ACGME) accredits Graduate Medical Education (GME) programs. Perhaps because of decreased funding available for GME, industry has had an increased role in funding in the GME environment, including funded residency and fellowship positions, awards, conferences, and meals. The concepts of disclosure and management of potential COI is important in the GME curriculum as residents are prepared for practice. Emergency medicine training programs should incorporate this education. Program directors should also assure that educational presentations to residents are free of commercial influences.
Business relationships in the GME environment may pose a COI. For example, for-profit staffing companies or management groups may staff a clinical area, with a primary goal of financial profit. This may conflict with the educational mission of the residency training program, which may inherently be less efficient. Residents must not be valued for their clinical labor, but their role is to gain the knowledge, skills, and abilities important to the practicing EP. It is crucial for the program director, chair, and faculty to protect the educational mission, even in a for-profit environment.
Continuing Medical Education. The Accreditation Council for Continuing Medical Education (ACCME) oversees nearly 1,900 organizations that strive to offer relevant, practice-based continuing medical education. 28 The ACCME has set standards for disclosure and management of potential COIs, including disclosures of potential COIs prior to and during scientific presentations, requiring them to be free of commercial bias, and limitations on commercial advertisement.
29, 30 However, compliance with disclosure is not universal. 31 Recognition and accurate presentation of information is essential to avoid bias. This should include accurate portrayal of evidence, critical literature review, and acknowledgement of limitations of research findings. 32 Misinformation may lead to patients being treated with interventions that may drive up costs, be ineffective, or produce harm. Emergency medicine professional organizations have an obligation to strive for conflict-free educational meetings.
Research, Publication, and Academic Advancement Industry collaboration in biomedical research can be mutually beneficial, particularly with the identification and development of new drugs and devices, provision of funding for studies, and industry channels for distribution. This relationship may concomitantly result in a variety of COIs that can undermine the very research it is supposed to support. The relationship between industry and biomedical research is quite extensive with industry financial sponsorship representing as much as 58% of total research funding, with an estimated one-fourth of investigators having industry affiliations and two-thirds of academic institutions with equity in businesses that sponsor research conducted in the same institution. 33 , 34 The impact of that relationship is significant, raising concerns about the openness of research and the strong potential for bias. The Office of Research Integrity for the NIH has disciplined 284 researchers for scientific misconduct yet almost half of those disciplined have subsequently received research grants totaling $123 million. 35 Publishing results that promote industry products is one way industry has exerted influence on medical research. Bias also may be introduced to medical research by ghost writing manuscripts on behalf of researchers, restricting the publication of negative trials, introducing discordance between results and conclusions, and the use of "seeding" trials designed after a drug has come to market specifically to influence physician and patient behavior-an example of marketing framed as science. 36, 37 Furthermore, restricting access to study data, preventing the sharing of data, and utilizing restrictive provisions in research contracts that allow industry sponsors to revise manuscripts and decide if results should be published or shared are all techniques that have been utilized by industry sponsors to exert inappropriate control over medical research. 38 Emergency medicine is not immune from industry influence. Birkhahn et al. 39 finds that emergency medicine academic faculty relationships with industry are common and that faculty benefited from the relationship socially, academically, and financially. Furthermore, in a national sampling, the numbers and types of interactions are consistent with those reported by other specialties. 40 Conflicts of interest in academic research and advancement are not limited to the involvement of industry. Researchers face intense competition and intense regulatory demands, while many academic institutions require their faculty members to maintain a certain level of grant, biomedical research, and publication productivity to advance along their tenure track. These pressures may lead to deviations in ethical behavior. One highly publicized example includes a research subject who received consent documents that were missing important information about adverse side effects experienced by research animals and who was enrolled despite a liver condition that should have excluded him. In the aftermath of this unfortunate death, it was discovered that both the principle investigator and the sponsoring institution had undisclosed financial interests in the company that was attempting to bring the therapy to market. 41 Thus, although we will never know the outcome if these disclosures had been made, hidden COIs have the potential to jeopardize patient welfare.
ORGANIZATIONS: HOSPITALS, SOCIETIES, SPECIALTY BOARDS, AND OTHER PROFESSIONAL ORGANIZATIONS
The primary mission of healthcare institutions should be to benefit patients. Other goals may include education and research. A goal of PMOs, for example, ACEP, SAEM, and AAEM, is to promote the interests of their membership. Other activities include providing educational and policy materials, legislative advocacy, and producing educational publications. Healthcare institutions and PMOs experience COIs through their receipt of outside funding, inequitable practices, and their use of compromised decision makers. The ethical challenge is that these interests may come into conflict with patient welfare.
Medical institutions and organizations may also experience real or perceived COIs. Institutional goals may include financial success, which may directly affect physicians and patients through payer-related policies that influence medical care. Untoward effects of such COIs may include decreased time spent with patients, inappropriate admission policies, and requirements to use particular medications or to restrict certain tests.
As for PMOs, some may be dependent on pharmaceutical, device, and biotechnology companies for support of their programs including satellite programs that contribute to their revenue. Some of these programs have the potential to drive sales and profit but not necessarily benefit patients. Assessing seven major physician PMOs, a recent review found that less than half exhibited transparency or compliance with the consensus best practice guidelines designed to lessen or eliminate the risks of both actual and perceived industry influence on PMOs. 42 In institutions and in PMOs, COIs may stem from individuals in leadership positions who have personal or professional loyalties and interests that differ from or compete with those of the institution or organization. 43 For instance, medical specialty boards may be governed by individuals with COIs between their fiduciary obligations to their boards, their diplomates, and their constituent patients and to their umbrella organization, the American Board of Medical Specialties.
Management of Potential COI Scenarios in the Practice of Emergency Medicine
As we analyze the case scenarios, we would emphasize that all of these should be viewed through the prism of optimizing care for patients in the emergency department (ED) in a manner that does not call into question whether the EP sought to uphold solely the patient's best interest.
1.
A new plastic surgeon has just come on staff at the hospital. She is very friendly and has offered to give your group a lecture. She leaves some business cards and popcorn for the staff and says she is happy to suture any wound. Is this ethical? Is there a COI present?
Receiving education and establishing interpersonal relationships are an important part of the practice of emergency medicine. As a field of medicine that interfaces with virtually all clinical specialties, emergency medicine by necessity requires knowledge of the common practices of subspecialists and trustful interactions therein to care for patients in the ED in an optimal fashion. Where the COI arises in this scenario is the provision of popcorn for the staff. While the gesture is friendly and likely appreciated, as we have shown, the underlying motivation is one of influencing the choice of care pathways for patients based on factors beyond the best interests of the patient alone. This would similarly apply if offered by other health care professionals (ambulance staff) or to other ED staff (nursing) who at least indirectly influence patient care decision making. In contrast, an offer of education by the plastic surgeon likely does not represent a COI in this case as the receipt of such training serves to enhance patient care if presented in an unbiased manner. Our suggested resolution would be to respectfully accept the offer or education and business cards but refuse the popcorn to bring the focus back to the care of the patient.
2. An article in a reputable journal suggests a rather drastic change in your approach to a clinical scenario. Are you mandated to change practice immediately? Should industry sponsorship color your opinion?
Clinical research is essential to improving patient care. Often, industry collaboration is an important research approach for answering important clinical questions. However, it is rare that a single research trial, even in a reputable journal of apparent extraordinary clinical impact, should immediately change patient care. The nature of scientific enquiry is that validity and reproducibility of results will confirm clinical applicability. These elements of the scientific method are important prerequisites to changing clinical practice. It is also clear that industry sponsorship is a real factor in assessing for COIs that may influence the reception and application of such research. Ideally, before changing clinical practice, reproduction of results in an unbiased (non-industry-sponsored) trial would be important to establishing the validity and reproducibility of the results. However, the specific details of the clinical situation, the rigor of the research trial execution, and the specific role of the industry sponsor will likely govern the clinical applicability for a specific case.
3. As a department chair, a salesperson for a new rapidonset platelet inhibitor "details, i.e., educates you with industry information" about the drug. He offers to sponsor a journal club without any mention of the drug at the event. He also offers to leave starter pack samples for patients with acute deep venous thrombosis who present after hours. Should you distribute these samples? Does it matter samples are reserved for patients who are deemed medically indigent?
This scenario clearly raises a number of COI flags. There is an abundance of evidence that drug company sponsorship of educational events is rarely without bias or commercial motivation. The use of starter packs to aid patient care is a practice that on the surface would seem to be beneficial to the care of patients, especially in those for whom the cost of new treatments may be cost-prohibitive. However, the nature of pharmaceutical economics, where programs to aid patients in copayments for new treatments often leads to higher drug costs through concomitant insurance coverage for the remaining price, makes such "free samples" problematic. A better resolution would be for the department and the hospital or health system to develop programs to aid impoverished patients obtain treatments through financial programs that are not tied to the use of particular brands of medication.
4. Your department is approached about participating in a research study by the department of neurology, a powerful department in your institution. After hours, since no research personnel will be on site, you will be asked to obtain informed consent. Does it make a difference if you will be paid for this activity or not? Does a potential conflict exist?
When considering involvement in a clinical research trial, the first and most important consideration should be the best interests of the individual patient. This might be framed by trying to answer the question as to whether the trial is attempting to address a clinical question that has the potential to improve the care of patients in the ED. If the answer to that is yes, then the fact that the trial originated from a department with whom you as an EP or department wish to establish a relationship may not represent a COI. Payment for obtaining informed consent should be confined to a reasonable level to cover the cost of the personnel time and infrastructure to do so in an appropriate manner. Exorbitant payments out of proportion with the effort involved will naturally shift the motivation for enrolling subjects to a monetary one that can jeopardize the integrity of the informed consent process and move toward a COI where the interest of the patient is not primarily upheld.
Although the Office of Inspector General generally defines an excessive reimbursement rate to be greater than $500/hour, any payment that unduly influences researchers to enroll patients beyond the motivation of scientific integrity may be considered excessive. It is also important to recognize that undue influences can extend beyond monetary consideration. For example, offers of co-authorship on publications can be of profound significance given their importance to academic promotion, institutional prestige, and command of resources for other personal and departmental priorities. It is easy to envision a modification of the presented scenario where in return for assistance in recruitment for a trial of little relevance to the ED, rather than monetary incentives, academic incentives are provided. We would contend that this still represents a COI as the primary driver should be the patient, in this case, the patient population of the ED when considering the ethical obligations of EPs.
Management of COIs
Management of COI should include disclosure, which allows readers, learners, and the public to assess the COI. Additionally, physicians should divest themselves from industry payments as much as possible. 44 Management of COIs is not simple or easy. Necessary but insufficient first steps in managing COIs are disclosure and recusal. Disclosure is not in and of itself a solution, as physicians do not routinely receive education on identifying and managing COIs. In CME for example, often, "disclosures are made but are structured or presented in a fashion that does not allow the audience to determine whether the potential conflict is meaningful or not." 45 In addition, disclosure may falsely convey the appearance of honesty, freeing individuals to express biases without fear of being discovered or sanctioned.
In addition to disclosure, physicians should recuse themselves from decisions for which a COI exists. For example, a physician on a board of directors may disclose a COI on a topic and participate in the discussion, but recuse oneself from a vote.
Sparse regulations exist concerning organizational and institutional COIs. While self-regulation may be the best solution, COI policies may pose an operational and financial burdens and put them at disadvantages with competitors. One suggestion is for PMOs to agree on COI policies, within antitrust guidelines, and implement them simultaneously so as to not put any PMO at a disadvantage. As noted above, cognitive dissonance theory suggests, "disclosure or even "management" of financial conflicts of interest . . . [does not] guarantee objectivity and prevent bias." 46 Therefore, COIs may best be managed by having all major stakeholders agreeing on the standards and being responsible for following them.
When identifying COIs, each entity must define the term "leadership" and seek to manage potential COIs "sensibly and effectively." 47 This requires a code of ethics, disclosure, an honor system, and general principles to manage relationships of a professional organization with industry. Disclosure and recusal must become routine, with policy violations having consequences within institutions or organizations.
At the individual practice level, disclosure and recusal have no role. Rather, practicing physicians must be on the lookout for the invisible hand that may be affecting them and always place the welfare of their patients above all else. Table lists some suggestions for the management of real or potential COIs. 48 
CONCLUSIONS
Conflicts of interest are common in the practice of emergency medicine and may be present in the areas of clinical practice, relations with industry, expert witness testimony, medical education, research, and organizations. Real, potential, and perceived conflicts of interest should be disclosed to all interested parties and, if appropriate, the individual should recuse oneself from decision making related to the COI. The interest of the individual patient should always be primary.
